about
Current Biochemical Monitoring and Risk Management of Immunosuppressive Therapy after TransplantationInvestigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.Oxidative and Nitrosative Stress in Stable Renal Transplant Recipients with Respect to the Immunosuppression Protocol - Differences or Similarities?Pharmacogenetics may Influence Tacrolimus Daily Dose, but not Urinary Tubular Damage Markers in the Long-Term Period after Renal Transplantation.Renalase Assessment With Regard to Kidney Function, Lipid Disturbances, and Endothelial Dysfunction Parameters in Stable Renal Transplant Recipients.Population pharmacokinetics of bisoprolol in patients with chronic heart failure.Monitoring of antibiotic consumption and development of resistance by enterobacteria in a tertiary care hospital.Population pharmacokinetics of carvedilol in patients with congestive heart failure.An inverse correlation between TNF alpha serum levels and heart rate variability in patients with heart failure.Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.Gender differences in oxidative and nitrosative stress parameters in kidney transplant patients on tacrolimus-based immunosuppression.Tacrolimus as a part of immunosuppressive treatment in kidney transplantation patients: sex differences.Erythrocytes' antioxidative capacity as a potential marker of oxidative stress intensity in neuroinflammation.Potential role of tacrolimus in erythrocytes' antioxidative capacity in long-term period after renal transplantationVariability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approachThe assessment of renalase: searching for the best predictor of early renal dysfunction by multivariate modeling in stable renal transplant recipientsAdverse effects of mycophenolic acid in renal transplant recipients: gender differencesThe predictive value of Klotho polymorphism, in addition to classical markers of CKD-MBD, for left ventricular hypertrophy in haemodialysis patients
P50
Q33801096-AD28DAC6-290D-4A49-9747-734E333C69D4Q35943046-0CDB1112-342D-4E1B-8EC0-A9059BB2F280Q37041316-2CBD40BE-F834-45BF-8CE4-D49A3A4075B5Q37041351-3B24BAC5-86A7-4C7E-A8FD-1FD1257C7F3CQ38724681-43C47B94-B30B-4E4C-8F14-6B718A638481Q39531576-73D7E3F0-D83B-46D4-BCF8-AA331D78752CQ40962548-9E12DC4E-638E-4D21-BEA0-B4F957335665Q50943845-2B2ED299-A98A-42B6-9DBB-F967D915A573Q51049807-1D97ED0A-2D64-4C29-BFB7-D64D90E2B247Q51104966-14C2EE2E-A1B4-46F6-9666-A67F1E7C561BQ51196312-46F025A8-1936-4448-B25F-8C1AED5B9BF1Q51297389-C8FBECCB-9E5A-4E34-B120-294AC51D81A6Q54545951-89022C49-6B0A-45F4-9B82-414F3E024816Q86679323-E289747E-A29F-4D00-9D54-2760EEF763D2Q86811842-6713559F-B536-47AE-B501-E68B477A8758Q87035751-E721B749-C068-48F2-8247-23A0F03A35C5Q91559753-133E823A-CCE5-4BE1-9C34-807EEB970545Q92674832-2EDB8BA5-5AEA-4131-8248-636644992593
P50
description
investigador
@es
researcher
@en
name
Nikola Stefanovic
@en
type
label
Nikola Stefanovic
@en
prefLabel
Nikola Stefanovic
@en
P31
P496
0000-0003-2599-7508